Live Breaking News & Updates on Top Line Results Expected

Stay updated with breaking news from Top line results expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Astria Therapeutics (ATXS) Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Astria Therapeutics (ATXS) Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Marcus Maurer , Jillc Milne , Christopher Morabito , Astria Therapeutics Inc , Institute Of Allergology At Charite , Current Cash Expected To Fund Company , Severe Attacks , Attacks Requiring Rescue Medications , Top Line Results Expected , Year End , Cash Expected , Fund Company , Call Today , Business Wire , Chief Medical Officer , Executive Director , Chief Executive ,

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway ....

Ha Afon , Dikla Czaczkes Akselbrad , Brian Ritchie , Czaczkes Akselbrad , Company Annual Report On Form , Polypid Ltd , Fund Polypid , More Than , Abdominal Colorectal Surgical Site , Interim Analysis , Conducted Once Approximately , Complete Their , Day Follow Up , Top Line Results Expected , Second Half , Intratumorally Reduced Tumor Volume , Improved Survival , New Animal , Financing Extends Company , Cash Runway Through Late Third Quarter , Beyond Expected Timing , Unblinded Interim Analysis , Potential Additional , Planned New Drug Application Submission , Call Scheduled , Corporate Highlights ,

Palatin Technologies : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 (Form 8-K)

Palatin Technologies : Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 (Form 8-K)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United States , Michaelb Raizman , Paul Arndt , Carl Spana , Jamese Hattersley , J Don Wang , Prnewswire Palatin Technologies Inc , Drug Administration , Exchange Commission , American Society Of Cataract , Palatin Technologies Inc , Product Development , Securities Exchange , Association For Research , Business Development , Ulcerative Colitis Currently Expected , Start Next Quarter , Top Line Results Expected , Second Half Calendar , Cash Equivalents , Cash Runway Through Calendar , Upcoming Events , Autoimmune Programs , New Drug Application , American Society , Refractive Surgery Annual ,